Facioscapulohumeral muscular dystrophy, usually called FSHD, is a genetic muscle disease driven by the abnormal activation of a gene called DUX4 that is normally silenced in adult tissue. It ranks among the most common inherited muscular dystrophies in adults, typically appearing between the ages of 15 and 30, and it follows a distinctive pattern: weakness that begins in the face, shoulders, and upper arms before spreading to other muscle groups over years or decades.1Neuromuscular Disorders. Overview of facioscapulohumeral dystrophy clinical features and diagnostic pathway The genetic story behind FSHD is unusual even by the standards of rare diseases, and the management landscape is shifting as gene-targeted therapies begin entering clinical trials.
Two Genetic Routes to the Same Disease
FSHD comes in two forms, both arriving at the same endpoint but through different genetic mechanisms. The more common form, FSHD1, accounts for roughly 95 percent of cases. It is caused by a contraction of a repetitive stretch of DNA known as the D4Z4 repeat array on chromosome 4. In unaffected people, this array typically contains 11 to 100 repeats. In FSHD1, the array shrinks to between 1 and 10 repeats.2Nature Genetics. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy But contraction alone is not enough. The shortened array only causes disease on a specific chromosomal background, sometimes called a “permissive” haplotype, that contains a signal allowing the DUX4 gene embedded within the repeat to produce a stable, translatable message.3PubMed Central. A unifying genetic model for facioscapulohumeral muscular dystrophy
The less common form, FSHD2, involves no repeat contraction at all. Instead, mutations in genes that regulate the chemical tagging of DNA, most commonly a gene called SMCHD1, strip away the molecular silencing marks that normally keep DUX4 shut off. The result is the same: DUX4 protein gets made in adult muscle where it should not be.4PubMed Central. SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome Both types of FSHD follow autosomal dominant inheritance, meaning a single copy of the genetic change from one parent is sufficient. Some people acquire the D4Z4 contraction as a new mutation rather than inheriting it, and those individuals may be genetic mosaics, carrying the contraction in some cells but not others, which can make genetic testing trickier.
How DUX4 Damages Muscle
DUX4 is a transcription factor, a protein that turns other genes on or off. In normal development, it is briefly active in very early embryos and in the germline, then permanently silenced. When it reawakens in adult muscle cells, it sets off a cascade of problems. Lab studies have shown that DUX4 expression represses MyoD, a key driver of muscle cell identity, interferes with the ability of muscle cells to mature and fuse into functional fibers, and disrupts the cell’s antioxidant defenses, leaving fibers more vulnerable to oxidative damage.5PubMed Central. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies
DUX4 is also directly toxic to cells. In animal models, overexpressing DUX4 in muscle produced abnormalities consistent with muscular dystrophy, and that toxicity depended on DUX4’s ability to bind DNA. When researchers blocked p53, a protein central to the cell’s self-destruction pathways, muscle tissue became resistant to DUX4-induced damage, suggesting that DUX4 kills muscle cells at least partly by triggering programmed cell death.6PubMed Central. DUX4, a Candidate Gene for Facioscapulohumeral Muscular Dystrophy, Causes p53-Dependent Myopathy In Vivo Additional work in human cell models found that DUX4 activates further damage pathways, including the accumulation of double-stranded RNA and stabilization of the MYC gene, both of which push cells toward apoptosis.7PLOS Genetics. DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy Understanding DUX4 took decades; for years the gene was dismissed as a pseudogene buried in “junk DNA” before researchers recognized it as the central driver of the disease.8PubMed Central. DUX4 at 25: how it emerged from “junk DNA” to become the cause of facioscapulohumeral muscular dystrophy
The Pattern of Weakness
The name facioscapulohumeral tells you where the disease starts: the face (facio), the shoulder blades (scapulo), and the upper arms (humeral). Early on, people often notice they cannot whistle, blow up a balloon, or drink through a straw because of facial muscle weakness. Shoulder blade winging, where the scapula lifts away from the rib cage when pushing against something, is another hallmark. Reaching overhead becomes harder as the muscles stabilizing the shoulder lose strength. The weakness tends to be strikingly asymmetric, often more pronounced on one side of the body than the other.9PubMed Central. Facioscapulohumeral muscular dystrophy
Over time, the disease typically descends. After the upper body, muscles in the lower legs often weaken next, sometimes causing foot drop, and eventually the hip and thigh muscles may be affected, making climbing stairs and getting up from a chair difficult. Trunk muscles, including the back extensors and abdominals, are frequently involved, more so than older clinical descriptions suggested. Imaging studies have found that fat infiltration of the back extensors is common and may undermine postural control even in patients who are otherwise mildly affected.10PubMed. Skeletal muscle imaging in facioscapulohumeral muscular dystrophy, pattern and asymmetry of individual muscle involvement
Wide Variability in Severity
FSHD is often described as one of the most variable inherited muscle diseases. Even within the same family carrying the same genetic mutation, one person may have minimal symptoms well into old age while a sibling requires a wheelchair in young adulthood. Research on families carrying very short D4Z4 repeat arrays (1 to 3 repeats) has documented a spectrum ranging from completely healthy carriers to patients with severe motor impairment.11BMJ Open. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1–3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry
At the severe end lies early-onset or infantile FSHD, which represents a small minority of cases but tends to be more debilitating. Children with very short repeat arrays (often 1 to 3 units) can show facial weakness and hearing loss in infancy or early childhood and may progress to wheelchair dependence before adulthood.12PubMed Central. Early-Onset Infantile Facioscapulohumeral Muscular Dystrophy: A Timely Review Meanwhile, longitudinal follow-up in adults suggests that for many patients, functional decline is slow. In one study tracking patients over roughly six and a half years, clinician-measured disease severity scores rose modestly, while patient-reported overall disability remained relatively stable. Meaningful decline was largely confined to those already moderately or severely affected at baseline.13PubMed Central. The Facioscapulohumeral Muscular Dystrophy Rasch-Built Overall Disability Scale (FSHD-RODS): Longitudinal Assessment of a Disease-Specific Patient Reported Outcome This slow pace is good news for everyday life, but it makes designing clinical trials harder because measuring a meaningful change over one or two years can be difficult.
Beyond the Muscles
FSHD is primarily a muscle disease, but it can affect other systems, particularly in more severely affected patients. Hearing loss is the most frequently reported extramuscular feature. A large registry study found hearing loss in about 13 percent of people with FSHD, with retinal abnormalities in about 4 percent and seizures in about 2 percent.14PubMed Central. Hearing Loss, Retinal Abnormality, and Seizures in People With Facioscapulohumeral Muscular Dystrophy Earlier, smaller studies that used more detailed testing found higher rates: one investigation using fluorescein angiography detected mild retinal blood vessel abnormalities in about half of evaluated patients and high-frequency hearing loss in roughly two-thirds.15PubMed. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy The discrepancy likely reflects how hard you look: many of these findings are subclinical and only show up with specialized testing. Still, the researchers who found those higher rates cautioned that these features, while part of the FSHD picture, are not reliable enough to use as diagnostic criteria on their own.
Respiratory function is another area worth watching. Most people with FSHD breathe normally throughout their lives, but a subset develop restrictive lung involvement, meaning the lungs cannot fully expand. One study found restrictive respiratory involvement in about 10 percent of their FSHD cohort overall, with a higher proportion in FSHD2 than FSHD1. Those with respiratory restriction were considerably more affected in other ways too: higher clinical severity scores, more limited shoulder range of motion, and greater wheelchair use.16PubMed Central. Restrictive Lung Involvement in Facioscapulohumeral Muscular Dystrophy Despite these findings, respiratory testing in FSHD appears underutilized. A US surveillance study found that only about 20 percent of people with confirmed FSHD underwent pulmonary function testing during the study period, even though roughly two-thirds of those tested showed at least mildly reduced lung capacity.17Neuromuscular Disorders. Respiratory function and evaluation in individuals with facioscapulohumeral muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking and Research Network
Pain and Fatigue Are Underappreciated
Because FSHD is defined by progressive weakness, pain and fatigue sometimes get overlooked. But they are extremely common. One study found that 80 percent of participants reported chronic persistent or periodic pain in multiple areas of the body, and about a third were severely fatigued.18Springer Link / Journal of Neurology. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy The pain is often musculoskeletal, driven by abnormal joint mechanics as weakened muscles fail to stabilize posture properly. The same study tested whether strength training or the medication albuterol could reduce pain and fatigue; unfortunately, neither showed a significant effect on those particular symptoms. This means pain management in FSHD often relies on conventional approaches: physical therapy, over-the-counter analgesics, and attention to posture and ergonomics rather than any FSHD-specific medication.
Getting a Diagnosis
Diagnosing FSHD typically begins with recognizing the characteristic pattern of weakness and confirming it with genetic testing. Because FSHD involves a repetitive DNA sequence rather than a simple point mutation, standard gene sequencing panels cannot detect it. The traditional method is Southern blotting, which measures the size of the D4Z4 repeat array. However, Southern blotting has technical limitations: it can struggle with borderline cases, may miss mosaicism, and sometimes produces ambiguous results.19PubMed. Molecular combing compared to Southern blot for measuring D4Z4 contractions in FSHD
Newer methods are improving diagnostic accuracy. Molecular combing allows laboratories to directly visualize the repeat arrays and distinguish chromosome 4 arrays from the similar-looking arrays on chromosome 10, offering more precise sizing and better detection of mosaicism. Optical genome mapping is another emerging tool. Updated best-practice guidelines now outline the strengths and limitations of each technology, including considerations for prenatal testing and pre-implantation genetic diagnosis for families who want it.20PubMed Central. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines For FSHD2, where the repeat array is normal in length, diagnosis requires additional steps: methylation analysis of the D4Z4 array and sequencing of candidate genes like SMCHD1.
Exercise and Physical Therapy
For years, people with muscular dystrophies were warned against exercise out of fear it would accelerate muscle damage. That concern has been largely put to rest for FSHD. A controlled trial showed that 12 weeks of low-intensity aerobic exercise improved fitness and maximum workload without any signs of increased muscle damage.21PubMed. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy A more comprehensive randomized controlled trial tested six months of combined aerobic, interval, and strength training done at home. It confirmed that this kind of program increases aerobic capacity, builds muscle strength and endurance, improves walking speed, and reduces fatigue, all without damaging muscle integrity as measured by blood markers and muscle biopsy.22PubMed Central. Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophy: A randomized controlled trial The takeaway is that structured, regular exercise is both safe and beneficial, and physical therapy should be considered a core part of FSHD management rather than an optional add-on.
Surgical Options for the Shoulder
When weakness of the muscles that anchor the shoulder blade becomes severe, the functional loss can be dramatic: people may lose the ability to raise their arms to shoulder height or above. Scapulothoracic arthrodesis, a surgery that fuses the shoulder blade to the rib cage, can substantially restore overhead reach. In one series, active abduction improved from about 47 degrees before surgery to about 102 degrees afterward, and forward flexion went from about 56 degrees to about 126 degrees.23PubMed Central. Scapulothoracic arthrodesis in facioscapulohumeral dystrophy with multifilament cable A systematic review of the procedure across multiple studies confirmed average gains of about 45 degrees in forward elevation and 40 degrees in abduction, along with cosmetic satisfaction and improved daily function.24PubMed Central. Outcomes of scapulothoracic fusion in facioscapulohumeral muscular dystrophy: A systematic review
The procedure is not for everyone. It works best when the deltoid and rotator cuff muscles still have reasonable strength; if those muscles are also severely weak, fusing the scapula will not help much because the arm still cannot be powered upward. Still, for well-selected patients, it is one of the most tangible functional gains available in FSHD today. Additional supportive measures include ankle-foot orthoses for foot drop and, in some cases, assistive devices for mobility and daily tasks as the disease progresses.
Emerging Therapies Targeting DUX4
Because DUX4 sits at the root of both FSHD types, shutting it off is the central goal of nearly every drug in development. Approaches fall into a few categories.
The furthest along clinically is losmapimod, a small molecule that inhibits the p38 kinase pathway, which regulates DUX4 expression. Preclinical work showed that blocking p38 significantly reduced DUX4 and its downstream gene targets in FSHD cell and mouse models.25PubMed Central. Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy Early-phase clinical trials produced promising functional improvements in muscle strength and reachable workspace, though they did not show a significant reduction in DUX4-driven gene expression in biopsied muscle, raising questions about the mechanism at work in human tissue.26PubMed Central. The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy A larger randomized, placebo-controlled phase 2b trial (REDUX4) was conducted to more rigorously assess its safety and efficacy.27The Lancet Neurology. Efficacy and safety of losmapimod in facioscapulohumeral muscular dystrophy (REDUX4): a randomised, double-blind, placebo-controlled, phase 2b trial The disconnect between functional benefits and molecular endpoints has been a subject of active debate in the FSHD community.
Antisense oligonucleotides, short synthetic snippets of modified DNA or RNA designed to intercept and degrade DUX4’s messenger RNA before it can be translated into protein, represent another strategy. Lab studies have demonstrated that targeted antisense molecules can achieve near-complete knockdown of DUX4 in FSHD cells.28PubMed Central. Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy Moving from lab dish to living animal, systemic delivery of an optimized antisense compound in an FSHD mouse model reduced DUX4 and its target genes by about half, which translated into measurable improvements: roughly a 52 percent gain in muscle strength, a 17 percent reduction in muscle fibrosis, and a 12 percent improvement in muscle atrophy.29PubMed Central. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model These results are encouraging but still preclinical; the challenge of delivering enough drug to enough muscle throughout the body remains substantial.
Epigenetic Editing with CRISPR
A more permanent approach under investigation uses CRISPR technology, not to cut the DNA (which carries risks in a highly repetitive region) but to re-silence DUX4 epigenetically. Researchers have shown that a deactivated Cas9 protein fused to a repressor domain can be directed to the DUX4 promoter in FSHD muscle cells, restoring the chemical marks that keep the gene quiet. This brought DUX4 messenger RNA down to about 30 to 50 percent of its original level and reduced the expression of its harmful downstream targets in parallel.30Molecular Therapy. A Muscle-Specific CRISPR/dCas9 Epigenetic Editing Platform for Facioscapulohumeral Muscular Dystrophy Importantly, this was achieved without disrupting the broader muscle gene-expression landscape, suggesting the approach is specific rather than scattershot.31PubMed Central. All-in-one vectors for epigenetic CRISPR inhibition of DUX4-fl in facioscapulohumeral muscular dystrophy
The appeal of epigenetic CRISPR strategies is conceptual elegance: rather than intercepting DUX4’s message after it is made (the antisense approach) or blocking a signaling pathway upstream (the losmapimod approach), this method aims to put the genie back in the bottle by restoring the silencing that failed in the first place. Delivery to muscle tissue throughout the body remains the main hurdle, as it does for most gene therapies, but the work has advanced to the point of packaging the guide RNA and repressor into single all-in-one viral vectors designed for efficiency.32Molecular Therapy. CRISPR/dCas9-mediated epimutation at D4Z4 induces repressive chromatin changes and inhibits DUX4 expression in facioscapulohumeral muscular dystrophy
Biomarkers and Tracking Progression
One of the practical obstacles in FSHD, both for patient care and for clinical trials, is measuring how the disease is changing. Muscle weakness progresses slowly and unevenly, and patients often compensate for weak muscles by using other ones, which can mask true decline on standard functional tests. MRI has emerged as a valuable tool: measuring intramuscular fat content and detecting early inflammation (STIR-positive signal) can reveal disease activity before functional loss becomes apparent, making imaging useful for both diagnosis and monitoring.33Neuromuscular Disorders. Muscle imaging in facioscapulohumeral muscular dystrophy (FSHD): Relevance for clinical trials, and expert recommendations
On the molecular side, researchers have developed a blood-based biomarker that reflects DUX4 activity without requiring a muscle biopsy. By measuring the expression of a panel of PAX7 target genes in peripheral blood, investigators found a signature that correlated with clinical severity in FSHD patients.34PubMed Central. The FSHD muscle–blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy A circulating biomarker would be a significant advance because it could make it easier to stratify patients for trials, track treatment response, and identify who is progressing faster without invasive procedures. Neither imaging biomarkers nor blood-based panels are yet standard in routine clinical practice, but both are increasingly used in research settings and are expected to shape the next generation of FSHD trial designs.
Patient Registries and Trial Readiness
Because FSHD is rare and variable, gathering enough patients for meaningful clinical trials is a genuine logistical challenge. Patient registries, databases that collect clinical and genetic information along with contact details of willing participants, have become essential infrastructure. The UK FSHD patient registry, for example, has already demonstrated its usefulness by supporting recruitment for natural history studies and providing baseline data to help calculate how large future trials need to be to detect a real treatment effect.35PubMed Central. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry Similar registries exist in the US, Italy, and other countries, and broader neuromuscular disease registries increasingly capture FSHD-specific data.36PubMed. Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease For patients, enrolling in a registry does not mean signing up for a trial, but it places them in the pipeline to be contacted when a relevant trial opens. Given how many potential therapies are now moving through preclinical and early clinical stages, the practical value of having a large, well-characterized patient population ready to participate is higher than it has ever been.